After FDR correction, we found that SGLT2 inhibitors were associated with Portal hypertension (B<0, Pval=2.80E-18), Uterine leiomyoma (B>0, Pval=3.03E-13), Glaucoma (B<0, Pval=1.25E-09), Rheumatism, unspecified and fibrositis (B>0, Pval=1.94E-16) and Secondary malignant neoplasm of digestive systems (B>0, Pval=1.08E-15) had significant causal associations (Figure 8, Supplementary Table S7). Here, SLC5A2 is linked to rheumatic disorder.